190 related articles for article (PubMed ID: 25209580)
1. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.
Idbaih A; Mokhtari K; Emile JF; Galanaud D; Belaid H; de Bernard S; Benameur N; Barlog VC; Psimaras D; Donadieu J; Carpentier C; Martin-Duverneuil N; Haroche J; Feuvret L; Zahr N; Delattre JY; Hoang-Xuan K
Neurology; 2014 Oct; 83(16):1478-80. PubMed ID: 25209580
[No Abstract] [Full Text] [Related]
2. Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors.
Mulcahy Levy JM; Foreman NK; Thorburn A
Autophagy; 2014; 10(11):2077-8. PubMed ID: 25484091
[TBL] [Abstract][Full Text] [Related]
3. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.
Protsenko SA; Semionova AI; Komarov YI; Aleksakhina SN; Ivantsov AO; Iyevleva AG; Imyanitov EN
Invest New Drugs; 2015 Oct; 33(5):1136-43. PubMed ID: 26286452
[TBL] [Abstract][Full Text] [Related]
4. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
D'Alonzo D; Glatz K
Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
[No Abstract] [Full Text] [Related]
5. BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia.
Michonneau D; Kaltenbach S; Derrieux C; Trinquand A; Brouzes C; Gibault L; North MO; Delarue R; Varet B; Emile JF; Brousse N; Hermine O
J Clin Oncol; 2014 Dec; 32(35):e117-21. PubMed ID: 24567436
[No Abstract] [Full Text] [Related]
6. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
[No Abstract] [Full Text] [Related]
7. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Sharman JP; Chmielecki J; Morosini D; Palmer GA; Ross JS; Stephens PJ; Stafl J; Miller VA; Ali SM
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e161-3. PubMed ID: 24997557
[No Abstract] [Full Text] [Related]
8. Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.
Kaplan HG
J Natl Compr Canc Netw; 2013 Dec; 11(12):1466-70. PubMed ID: 24335681
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: A case report and review of the literature.
Branco B; Comont T; Ysebaert L; Picard M; Laurent C; Oberic L
Eur J Haematol; 2019 Oct; 103(4):444-448. PubMed ID: 31376203
[No Abstract] [Full Text] [Related]
10. Secondary histiocytic sarcoma with BRAF
Venkataraman V; Massoth LR; Sullivan RJ; Friedmann AM
Pediatr Blood Cancer; 2020 May; 67(5):e28200. PubMed ID: 32037654
[No Abstract] [Full Text] [Related]
11. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
12. Sustained Response to Vemurafenib in a BRAF
Prager GW; Koperek O; Mayerhoefer ME; Muellauer L; Wrba F; Niederle B; Zielinski CC; Raderer M
Thyroid; 2016 Oct; 26(10):1515-1516. PubMed ID: 27532222
[No Abstract] [Full Text] [Related]
13. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
15. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis.
Forschner A; Niessner H; Bauer J; Bender B; Garbe C; Meier F
JAMA Dermatol; 2013 May; 149(5):642-4. PubMed ID: 23677116
[No Abstract] [Full Text] [Related]
17. Pilomyxoid astrocytoma treated successfully with vemurafenib.
Skrypek M; Foreman N; Guillaume D; Moertel C
Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190
[TBL] [Abstract][Full Text] [Related]
18. Histiocytic sarcoma arising from thyroid gland with BRAF V600E mutation.
Ge R; Chang Y; Gan Y; Zhu H; Liu C
Pathology; 2020 Aug; 52(5):603-605. PubMed ID: 32600657
[No Abstract] [Full Text] [Related]
19. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
20. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]